keyword
https://read.qxmd.com/read/38616991/effect-of-sarcopenia-on-10-year-risk-of-atherosclerotic-cardiovascular-disease-in-patients-with-type-2-diabetes-mellitus
#21
JOURNAL ARTICLE
Long-Fei Xia, Jing-Bo Li, Guo-Sheng Tian, Wei-Ran Jiang, Yao-Shuang Li, Chen-Ying Lin, Hui-Na Qiu, Fan Wu, Jun-Jia Wang, Chun-Jun Li, Jing-Na Lin
OBJECTIVE: To investigate the impact of sarcopenia on the 10-year risk of atherosclerotic cardiovascular disease (ASCVD) among individuals with type 2 diabetes mellitus (T2DM). METHODS: This study included the clinical, laboratory, and body composition data of 1491 patients with T2DM who were admitted to the Department of Endocrinology and Metabolism at Tianjin Union Medical Center from July 2018 to July 2023. The China-PAR model was utilized to evaluate cardiovascular disease risk...
2024: Diabetes, Metabolic Syndrome and Obesity
https://read.qxmd.com/read/38605208/distinguishing-health-related-parameters-between-metabolically-healthy-and-metabolically-unhealthy-obesity-in-women
#22
JOURNAL ARTICLE
Fernando Mendonça, Pietra Soares, Telma Moreno, Paula Freitas, Ilda Rodrigues, Diana Festas, Jorge Pedro, Ana Varela, Ana Fernandes, Rúben Fernandes, Raquel Soares, Eduardo Lima Costa, Carla Luís
BACKGROUND: Obesity represents a global health crisis, yet a dichotomy is emerging with classification according to the metabolic state into metabolically healthy obesity (MHO) and metabolically unhealthy obesity (MUO). This study aimed to identify distinctive systemic clinical/endocrinological parameters between MHO individuals, employing a comprehensive comparative analysis of 50 biomarkers. Our emphasis was on routine analytes, ensuring cost-effectiveness for widespread use in diagnosing metabolic health...
April 11, 2024: International Journal of Obesity
https://read.qxmd.com/read/38604183/international-roadshow-new-advances-in-endocrinology-and-metabolic-diseases
#23
JOURNAL ARTICLE
Charlotte Steenblock, Maha M Saber-Ayad, Stefan R Bornstein
Dear Readers,Currently, there is a myriad of new developments in the field of endocrinology. In particular, significant strides have been made in the development of poly-agonists for the treatment of type 2 diabetes and obesity 1 2. Poly-agonists represent a novel therapeutic approach by combining multiple actions within a single molecule, targeting multiple receptors simultaneously to achieve enhanced efficacy. These innovative compounds aim to address the complex interplay of hormonal pathways involved in glucose regulation and metabolism, offering potential breakthroughs in the management of diabetes and obesity...
April 2024: Hormone and Metabolic Research
https://read.qxmd.com/read/38599612/efficacy-and-safety-of-once-weekly-subcutaneous-semaglutide-in-adults-with-overweight-or-obesity-systematic-review-with-meta-analysis
#24
JOURNAL ARTICLE
Gilson Dorneles, Ellen Algeri, Gerhard Lauterbach, Marcelo Pereira, Brigida Fernandes
BACKGROUND: To evaluate the efficacy and safety of once-weekly subcutaneous semaglutide treatment in overweight or obese patients without type 2 diabetes. METHODS: Randomized clinical trials that accessed the impact of once-weekly semaglutide on body weight and safety outcomes in overweight or obese patients were retrieved from Pubmed, EMBASE, and Lilacs up to November 2023. Risk of bias was assessed with RoB 2.0, and certainty of evidence (CoE) with GRADE. We conducted a random-effects meta-analysis...
April 10, 2024: Experimental and Clinical Endocrinology & Diabetes
https://read.qxmd.com/read/38599201/systemic-co-administration-of-low-dose-oxytocin-and-glucagon-like-peptide-1-additively-decreases-food-intake-and-body-weight
#25
JOURNAL ARTICLE
Yuko Maejima, Shoko Yokota, Shizu Hidema, Katsuhiko Nishimori, Heidi de Wet, Kenju Shimomura
INTRODUCTION: GLP-1 receptor agonists are the number one drug prescribed for the treatment of obesity and type 2 diabetes. These drugs are not, however, without side-effects and in an effort to maximize therapeutic effect while minimizing adverse effects, gut hormone co-agonists received considerable attention as new drug targets in the fight against obesity. Numerous previous reports identified the neuropeptide oxytocin (OXT) as a promising anti-obesity drug. The aim of this study is to evaluate OXT as a possible co-agonist for GLP-1 and examine the effects of its co-administration on food intake (FI) and body weight (BW) in mice...
April 10, 2024: Neuroendocrinology
https://read.qxmd.com/read/38599200/the-26rfa-qrfp-gpr103-neuropeptidergic-system-a-key-regulator-of-energy-and-glucose-metabolism
#26
REVIEW
Mélodie Devère, Saloua Takhlidjt, Gaëtan Prévost, Nicolas Chartrel, Jérôme Leprince, Marie Picot
BACKGROUND: Obesity and type 2 diabetes are strongly associated pathologies, currently considered as a worldwide epidemic problem. Understanding the mechanisms that drive the development of these diseases would enable to develop new therapeutic strategies for their prevention and treatment. Particularly, the role of the brain in the energy and glucose homeostasis has been studied for two decades. In specific, the hypothalamus contains well-identified neural networks regulating appetite and potentially also glucose homeostasis...
April 10, 2024: Neuroendocrinology
https://read.qxmd.com/read/38597653/prevalence-and-predictors-of-gestational-diabetes-mellitus-in-sub-saharan-africa-a-10-year-systematic-review
#27
REVIEW
Daniel Ataanya Abera, Christopher Larbie, James Abugri, Mina Ofosu, Mohamed Mutocheluh, Julius Dongsogo
BACKGROUND: Gestational diabetes mellitus (GDM) remains a global public health problem, which affects the well-being of mothers and their children in sub-Saharan Africa (SSA). Studies conducted in different geographical areas provide varied results on its prevalence and predictors. Understanding the extent and predictors of GDM in SSA is important for developing effective interventions and policies. Thus, this review aimed to investigate the prevalence of GDM and its predictive factors in sub-Saharan Africa...
May 2024: Endocrinology, Diabetes & Metabolism
https://read.qxmd.com/read/38596222/gut-microbiota-and-therapy-for-obesity-and-type-2-diabetes
#28
REVIEW
Luyao Zhang, Pai Wang, Juan Huang, Yanpeng Xing, F Susan Wong, Jian Suo, Li Wen
There has been a major increase in Type 2 diabetes and obesity in many countries, and this will lead to a global public health crisis, which not only impacts on the quality of life of individuals well but also places a substantial burden on healthcare systems and economies. Obesity is linked to not only to type 2 diabetes but also cardiovascular diseases, musculoskeletal disorders, and certain cancers, also resulting in increased medical costs and diminished quality of life. A number of studies have linked changes in gut in obesity development...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38588683/direct-to-consumer-services-improving-access-to-care-for-people-with-diabetes-and-obesity
#29
JOURNAL ARTICLE
Talha Burki
No abstract text is available yet for this article.
April 5, 2024: Lancet Diabetes & Endocrinology
https://read.qxmd.com/read/38587099/the-interaction-between-gut-microbiome-and-bone-health
#30
JOURNAL ARTICLE
Francesco Inchingolo, Angelo Michele Inchingolo, Fabio Piras, Laura Ferrante, Antonio Mancini, Andrea Palermo, Alessio Danilo Inchingolo, Gianna Dipalma
PURPOSE OF REVIEW: This review critically examines interconnected health domains like gut microbiome, bone health, interleukins, chronic periodontitis, and coronavirus disease 2019 (COVID-19), offering insights into fundamental mechanisms and clinical implications, contributing significantly to healthcare and biomedical research. RECENT FINDINGS: This review explores the relationship between gut microbiome and bone health, a growing area of study. It provides insights into skeletal integrity and potential therapeutic avenues...
April 12, 2024: Current Opinion in Endocrinology, Diabetes, and Obesity
https://read.qxmd.com/read/38586922/a-prospective-study-on-the-prevalence-of-at-risk-mash-in-patients-with-type-2-diabetes-mellitus-in-the-united-states
#31
JOURNAL ARTICLE
Nikita Mittal, Harris Siddiqi, Egbert Madamba, Lisa Richards, Ricki Bettencourt, Veeral Ajmera, Rohit Loomba
BACKGROUND: There are limited data on the prevalence and treatment of at-risk metabolic dysfunction-associated steatohepatitis (MASH) among patients with type 2 diabetes (T2DM) in the United States. AIM: To estimate the prevalence of at-risk MASH in a prospectively recruited cohort of adults with T2DM using new nomenclature endorsed by multiple societies. METHODS: This prospective study enrolled adults aged ≥50 with T2DM from primary care and endocrinology clinics in southern California from 2016 to 2023...
April 8, 2024: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/38586462/editorial-oxidative-stress-and-inflammation-in-cardiometabolic-disorders
#32
EDITORIAL
Aleksandra Klisic, Dimitrios Patoulias, Esma R Isenovic
No abstract text is available yet for this article.
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38586455/meal-timing-and-its-role-in-obesity-and-associated-diseases
#33
REVIEW
Beeke Peters, Janna Vahlhaus, Olga Pivovarova-Ramich
Meal timing emerges as a crucial factor influencing metabolic health that can be explained by the tight interaction between the endogenous circadian clock and metabolic homeostasis. Mistimed food intake, such as delayed or nighttime consumption, leads to desynchronization of the internal circadian clock and is associated with an increased risk for obesity and associated metabolic disturbances such as type 2 diabetes and cardiovascular diseases. Conversely, meal timing aligned with cellular rhythms can optimize the performance of tissues and organs...
2024: Frontiers in Endocrinology
https://read.qxmd.com/read/38585653/research-trends-on-the-gut-microbiota-in-endocrine-metabolism-a-thematic-and-bibliometric-analysis
#34
JOURNAL ARTICLE
Durmus Doğan, Taylan Çelik
BACKGROUND: Gut microbiota studies in the field of endocrinology metabolism have attracted increasing attention in recent years. To comprehensively assess the evolving landscape of this research field, we conducted a thorough bibliometric analysis of gut microbiota studies in endocrinology metabolism indexed in the Web of Science database. METHODS: We collected and analyzed 3,339 original research articles and reviews published from 1972 to 2023. Using various bibliometric indicators, we investigated publication trends, country contributions, international collaborations, prolific authors, top journals, and influential articles...
2024: Frontiers in Cellular and Infection Microbiology
https://read.qxmd.com/read/38585386/olfactory-function-in-diabetes-mellitus
#35
REVIEW
Beata Sienkiewicz-Oleszkiewicz, Thomas Hummel
Diabetes mellitus (DM) is an increasingly common disease in both children and adults. In addition to neuronal and/or vascular disorders, it can cause chemosensory abnormalities including olfactory deterioration. The purpose of this article is to summarize current knowledge on olfactory function in DM, highlighting the impact of co-morbidities, especially obesity, thyroid dysfunction, chronic kidney disease and COVID-19 on olfactory outcomes. Research to date mostly shows that olfactory impairment is more common in people with diabetes than in the general population...
June 2024: Journal of Clinical & Translational Endocrinology
https://read.qxmd.com/read/38579777/the-interplay-of-glucose-dependent-insulinotropic-polypeptide-in-adipose-tissue
#36
REVIEW
Samrin Kagdi, Sulayman Lyons, Jacqueline L Beaudry
Adipose tissue was once known as a reservoir for energy storage but is now considered a crucial organ for hormone and energy flux with important effects on health and disease. Glucose-dependent insulinotropic polypeptide (GIP) is an incretin hormone secreted from the small intestinal K-cells, responsible for augmenting insulin release, and has gained attention for its independent and amicable effects with glucagon-like peptide-1 (GLP-1), another incretin hormone secreted from the small intestinal L-cells. The GIP receptor (GIPR) is found in whole adipose tissue, whereas the GLP-1 receptor (GLP-1R) is not, and some studies suggest that GIPR action lowers body weight and plays a role in lipolysis, glucose/lipid uptake/disposal, adipose tissue blood flow, lipid oxidation, and free-fatty acid (FFA) re-esterification that may or may not be influenced by other hormones such as insulin...
April 1, 2024: Journal of Endocrinology
https://read.qxmd.com/read/38579770/from-classical-dualistic-antagonism-to-hormone-synergy-potential-of-overlapping-action-of-glucagon-insulin-and-glp-1-for-the-treatment-of-diabesity
#37
REVIEW
Svjatoslavs Kistkins, Othmar Moser, Vitālijs Ankudovičs, Dmitrijs Bliznuks, Timurs Mihailovs, Sergejs Lobanovs, Harald Sourij, Andreas F H Pfeiffer, Valdis Pirags
The increasing prevalence of "diabesity," a combination of type 2 diabetes and obesity, poses a significant global health challenge. Unhealthy lifestyle factors, including poor diet, sedentary behavior, and high stress levels, combined with genetic and epigenetic factors, contribute to the diabesity epidemic. Diabesity leads to various significant complications such as cardiovascular diseases, stroke, and certain cancers. Incretin-based therapies, such as GLP-1 receptor agonists and dual hormone therapies, have shown promising results in improving glycemic control and inducing weight loss...
April 1, 2024: Endocrine Connections
https://read.qxmd.com/read/38569700/portuguese-observational-cross-sectional-clinical-imaging-study-protocol-to-investigate-central-dopaminergic-mechanisms-of-successful-weight-loss-through-bariatric-surgery
#38
JOURNAL ARTICLE
Marta Lapo Pais, Joana Crisóstomo, Antero Abrunhosa, Miguel Castelo-Branco
INTRODUCTION: Bariatric surgery (BS) is the treatment of choice for refractory obesity. Although weight loss (WL) reduces the prevalence of obesity-related comorbidities, not all patients maintain it. It has been suggested that central mechanisms involving dopamine receptors may play a role in successful WL. This protocol describes an observational cross-sectional study to test if the binding of central dopamine receptors is similar in individuals who responded successfully to BS and age- and gender-matched normal-weight healthy individuals (controls)...
April 2, 2024: BMJ Open
https://read.qxmd.com/read/38569684/metabolic-dysfunction-associated-profiles-and-subsequent-site-specific-risk-of-obesity-related-cancers-among-chinese-patients-with-diabetes-a-retrospective-cohort-study
#39
JOURNAL ARTICLE
Sarah Tsz Yui Yau, Eman Leung, Martin Chi Sang Wong, Chi Tim Hung, Ka Chun Chong, Albert Lee, Eng Kiong Yeoh
OBJECTIVES: To compare metabolic dysfunction-associated profiles between patients with diabetes who developed different obesity-related site-specific cancers and those who remained free of cancer during follow-up. DESIGN: Retrospective cohort study. SETTING: Public general outpatient clinics in Hong Kong. PARTICIPANTS: Patients with diabetes without a history of malignancy (n=391 921). PRIMARY OUTCOME MEASURES: The outcomes of interest were diagnosis of site-specific cancers (colon and rectum, liver, pancreas, bladder, kidney and stomach) during follow-up...
April 3, 2024: BMJ Open
https://read.qxmd.com/read/38568373/asprosin-its-function-as-a-novel-endocrine-factor-in-metabolic-related-diseases
#40
REVIEW
Y Zhang, P Yang, X Zhang, S Liu, K Lou
BACKGROUND AND PURPOSE: Asprosin was discovered as a new endocrine hormone originating from fibrillin-1 cleavage that plays a crucial role in various metabolic-related diseases, such as obesity, nonalcoholic fatty liver disease (NAFLD), diabetes, polycystic ovary syndrome (PCOS), and cardiovascular diseases. The purpose of this review is to describe the recent advancements of asprosin. METHOD: Narrative review. RESULT: This comprehensive review explores its tissue-specific functions, focusing on white adipose tissue, liver, hypothalamus, testis, ovary, heart, pancreas, skeletal muscle, and kidney...
April 3, 2024: Journal of Endocrinological Investigation
keyword
keyword
4464
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.